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Abstract
Background: The process of translation occurs at a nexus point downstream of a number of signal pathways and
developmental processes. Modeling activation of the PTEN/AKT/mTOR pathway in the Em-Myc mouse is a valuable tool to
study tumor genotype/chemosensitivity relationships in vivo. In this model, blocking translation initiation with silvestrol, an
inhibitor of the ribosome recruitment step has been showed to modulate the sensitivity of the tumors to the effect of
standard chemotherapy. However, inhibitors of translation elongation have been tested as potential anti-cancer therapeutic
agents in vitro, but have not been extensively tested in genetically well-defined mouse tumor models or for potential
synergy with standard of care agents.
Methodology/Principal Findings: Here, we chose four structurally different chemical inhibitors of translation elongation:
homoharringtonine, bruceantin, didemnin B and cycloheximide, and tested their ability to alter the chemoresistance of Em-
myc lymphomas harbouring lesions in Pten, Tsc2, Bcl-2,o reIF4E. We show that in some genetic settings, translation
elongation inhibitors are able to synergize with doxorubicin by reinstating an apoptotic program in tumor cells. We
attribute this effect to a reduction in levels of pro-oncogenic or pro-survival proteins having short half-lives, like Mcl-1, cyclin
D1 or c-Myc. Using lymphomas cells grown ex vivo we reproduced the synergy observed in mice between chemotherapy
and elongation inhibition and show that this is reversed by blocking protein degradation with a proteasome inhibitor.
Conclusion/Significance: Our results indicate that depleting short-lived pro-survival factors by inhibiting their synthesis
could achieve a therapeutic response in tumors harboring PTEN/AKT/mTOR pathway mutations.
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Introduction
Recent large scale analysis of gene mutations, deletions, and
amplifications in human tumors have revealed that cancers exhibit
on average ,60–90 genetic alterations per tumor [1,2]. The
majority of these genetic alterations target players in a limited set
of signalling transduction pathways or processes [1,2]. These
analyses suggest that therapeutic targeting of specific altered
oncogenes may be too narrow an approach for drug development,
but rather targeting nodes that reside downstream of these
pathways may offer broader acting therapies [1,2]. Indeed, the
process of translation is a node for several signalling pathways and
has been shown to be a potential therapeutic target.
One approach to study genotype-drug response relationships
has been the use of mechanism-based mouse cancer models, such
as the Em-Myc lymphoma model [3]. In this model, activating
lesions in PI3K/AKT/mTOR signalling not only accelerate
tumorigenesis, but also modulate chemosensitivity [4,5,6]. Resis-
tance to doxorubicin (Dxr) or cyclophosphamide in myr-AKT
activated or PTEN
+/2Em-Myc lymphomas has been linked to (a)
defective apoptotic program(s) dependent on increased mTOR
activity and linked to elevated translation initiation rates.
mTOR impinges on the translation process by regulating the
assembly of eukaryotic initiation factor (eIF) 4F, a heterotrimeric
complex consisting of: eIF4E, a cap (m
7GpppN, where N in any
nucleotide) binding protein; eIF4A, a DEAD-box RNA helicase;
and eIF4G, a large scaffolding protein involved in recruiting the
40S ribosome (and associated factors) [7]. Increased eIF4F activity
is thought to increase translation rates since eIF4E is the least
abundant translation factor and initiation is generally rate-limiting
for translation [8,9]. Increased eIF4F activity stimulates preferen-
tially the translation of mRNA with G+C rich, highly-structured
59UTRs (weak mRNAs) without significantly affecting translation
of mRNAs with short and unstructured 59UTRs (strong mRNAs)
[10,11,12]. Typically, strong mRNAs encode house keeping genes
like b-actin and GAPDH whereas weak mRNAs encode potent
growth and survival factors, such as the angiogenesis factors
VEGF and FGF-2, the proto-oncoproteins cyclin D1 and c-Myc,
and the pro-survival factors myeloid cell leukemia sequence 1
(Mcl-1) and survivin [13,14,15].
Preventing eIF4F assembly by inhibiting mTOR signalling with
rapamycin (Rap) [6,16] or blocking eIF4F activity with silvestrol,
an inhibitor of the ribosome-recruitment step of translation
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mTOR signalling to the cytotoxic action of Dxr, though neither of
these treatments on their own is effective. eIF4E is oncogenic in
vivo and in Em-Myc lymphomas over-expressing this factor,
rapamycin is unable to modulate chemosensitivity whereas
silvestrol can [6,16,18,19]. The mechanism by which Rap and
silvestrol alter chemosensitivity is not clear but may involve
remodelling of the oncoproteome through differential mRNA
recruitment into initiation complexes [13], with preferred
inhibition of ‘‘weak’’ mRNAs encoding pro-survival signals, such
as Mcl-1 [4,17,20]
Interestingly, several inhibitors of translation elongation have
also been reported to exert significant anti-cancer activity. This
creates somewhat of a paradox as elongation inhibitors are not
expected to be selective in their mode of action and would be
expected to possess a narrow therapeutic window. Yet, homo-
harringtonine (HHT) (a cephalotaxus alkaloid) has demonstrated
activity in patients with chronic myeloid leukemia after imatinib
failure [21]. Aplidine [a didemnim (Did) family member] has
shown activity in phase I clinical trials for many cancer types but
especially in advanced medullar thyroid carcinoma [22]. Bru-
ceantin [(Bru); a quassinoid], showed efficacy in a RPMI 8226
human-SCID xenografts mouse model [23].
To address whether inhibitors of translation elongation could
also synergize with DNA damaging agents (e.g. Dxr), we tested the
potential of four elongation inhibitors to modulate chemosensitiv-
ity in the Em-myc model harboring lymphomas with loss of Pten or
Tsc2 or over-expressing Bcl-2 or eIF4E. We find that all inhibitors
tested can alter the chemosensitivity of tumors harboring activated
mTOR, but not in Bcl-2-driven tumors. We observe that these
compounds reduce Mcl-1 levels and postulate that they cause a
reduction in the levels of short-lived proteins, some of which are
pro-survival factors. We propose that this resets the apoptotic
program. These results provide a mechanism by which elongation
inhibitors sensitize cells to apoptotic triggers.
Materials and Methods
Ethics Statement
Animal studies were approved by the McGill University Faculty
of Medicine Animal Care Committee.
Compound preparation and storage
HHT (Sigma-Aldrich, St.-Louis, MO), cycloheximide (CHX)
(BioShop, Burlington, On), didemnin B (Did B) (NCI-DTP), Bru
(NCI-DTP) and MG132 (Sigma-Aldrich, St.-Louis, MO) were
resuspended in DMSO and stored at 270uC. Doxorubicin
(Sigma-Aldrich, St.-Louis, MO) was dissolved in water and stored
at 4uC. Rap (LC Laboratories, Woburn, MA) was resuspended in
100% ethanol and stored at 270uC.
Cell culture and in vitro synergy assays
Mice bearing palpable Tsc2
+/2Em-myc lymphomas were sacri-
ficed, lymph nodes extracted, and tumor cells harvested by gently
crushing the lymph nodes between two microscope slides. Cells
were then put into culture in B-cell medium (BCM) (50%
DMEM/50% IMDM) (Invitrogen, Carlsbad, CA), supplemented
with 55 mM b-mercaptoethanol, Pen/Strep (Invitrogen, Carlsbad,
CA) and Glutamine (Invitrogen, Carlsbad, CA) over an irradiated
NIH3T3 feeder layer. For ex vivo synergy experiments, 10
5 Tsc2
+/2
Em-myc cells were plated in 96-well plates in the presence of HHT
(0.625 nM to 160 nM), MG132 (0.039 mMt o2 0 mM), Dxr
(0.0975 mg/ml to 10 ug/ml) or various combinations thereof.
Sixteen hours later, cell viability was assessed with the CellTiter
96H Non-Radioactive Cell Proliferation Assay (MTT) according to
the manufacturer recommendations (Promega, Madison, WI).
Synergy between compound treatments was calculated using
compusyn software (ComboSyn Inc.).
Treatment studies
The generation of Pten
+/2Em-Myc, Tsc2
+/2Em-Myc, Em-Myc/
Bcl-2 and Em-Myc/eIF4E lymphomas has been previously
described [6,16]. A total of 10
6 secondary lymphoma cells were
injected into the tail vein of 6–8 week old female C57BL/6 mice.
When well-palpable tumors arose, mice were treated with Dxr
(once at 10 mg/kg), Rap (4 mg/kg daily for 5 days), HHT
(0.25 mg/kg daily for 5 days), Bru (0.5 mg/kg daily for 5 days),
Did B (0.05 mg/kg daily for 5 days), or CHX (12.5 mg/kg for 5
days). The compounds were diluted into 5.2% PEG400/5.2%
Tween 80 immediately prior to intraperitoneal (IP) injection. In
combination studies, Rap, HHT, Bru, Did B or CHX were
administered once daily for 5 consecutive days, with Dxr being
administered once on day two. The presence of the tumors was
monitored by daily palpation and blood smears (twice/week)
stained with Hema-3H stain (Fisher Scientific, Pittsburg, PA).
Tumor-free survival is defined as the time between tumor
disappearance and reappearance of a palpable lymphoma. Overall
survival is defined as the time after tumor disappearance required
for the mice to reach a terminal stage at which point the animals
were sacrificed. The data were analyzed in the Kaplan-Meier
format using the log-rank (Mantel-Cox) test for statistical
significance (SigmaStat software).
TUNEL (terminal deoxyribonucleotide transferase-
mediate nick-end labeling) assays and Western blotting
For TUNEL assays, 6–8 week old C57Bl/6 mice bearing well-
palpable tumors were treated once with Rap (4 mg/kg), HHT
(0.25 mg/kg), Bru (0.5 mg/kg), Did B (0.5 mg/kg), or CHX
(12.5 mg/kg) and the next day were treated again with or without
Dxr (10 mg/kg). Four hours later, tumors were removed and fixed
in 10% Neutral Buffered Formalin (NBF) overnight and
embedded in paraffin. Tumor sections (4 mm) were used in
TUNEL assays according to the manufacturer’s recommendations
(Roche Applied Science, Indianapolis, IN) and stained with
Hematoxylin to visualize cell boundaries. For Western blot
analysis, mice were treated for the indicated times, the tumors
harvested, total cell lysates prepared using RIPA buffer, and
proteins separated by SDS-PAGE. The antibodies used were: b-
actin (Sigma-Aldrich, St.-Louis, MI), cleaved PARP (Cell Signal-
ling, Beverly, MA), Mcl-1 (Rockland antibodies, Gilbertsville, PA),
cyclin D1 (Cell signalling, Beverly, MA), c-Myc (Santa cruz
biotechnology, Santa Cruz, CA), and a-tubulin (Sigma-Aldrich,
St.-Louis, MI). Total protein content of each extract was
determined using the DC protein assay (Biorad, Richmond, CA).
Ribosome binding and polysome analysis
Ribosome binding experiments were performed as previously
described [24]. In brief,
32P-labelled CAT mRNA was incubated
with rabbit reticulocyte lysate in the presence of 10 mM
HHT+600 mM CHX, 10 mM Bru+600 mM CHX, CHX alone
or no compounds for 10 min at 30uC. Translation initiation
complexes formed were resolved on 10–30% glycerol gradients by
centrifugation for 3.5 h at 39,000 rpm (187,0006g) in an SW41
rotor. The gradients were then fractionated using a UA-6 UV
detector (ISCO, Lincoln, NE) with a Brandel tube piercer and the
radioactivity in each fraction was determined by Cerenkov
counting.
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were injected IP with HHT (0.25 mg/kg) or Bru (0.5 mg/kg)
diluted into 5.2% PEG400/5.2% Tween 80. Two hours later, the
tumors were harvested, washed with PBS and lysed in hypotonic
lysis buffer (5 mM Tris7.5, 2.5 mM MgCl2, 1.5 mM KCl, 2 mM
DTT, 1% Triton X-100, 0.5% Sodium Deoxycholate) in the
presence of 100 mg/mL CHX. The extracts were centrifuged
through a 10–50% sucrose gradient at 35,000 rpm (150,0006g)
for 2 h in an SW40 rotor, followed by fractionation of the
gradients using a UA-6 UV detector (ISCO, Lincoln, NE) using a
Brandel tube piercer. Total RNA from every second fraction was
isolated using Trizol (Invitrogen Carlsbad, CA). The amount of
Mcl-1, Cyclin D1, c-Myc and b-actin mRNAs were detected by
qRT-PCR using the Roche Diagnostics LightCycler instrument
and LightCycler RNA master SYBR green I kit according to the
manufacturer’s instruction. The primers used for qRT-PCR were:
c-Myc:
59TGCGACTGACCCAACATCAG
39 and
59CCTGTC-
CTGGCTCGCAGATT
39; Cyclin D1:
59CAGGTTCCTGTT-
CACAATACCTCA
39 and
59AGACCGCCCACCTGCC
39, Mcl-1
59AGCACATTTCTGATGCCGCCT
39 and
59GTGCCTTTGT-
GGCCAAACACT
39; and b-actin:
59TCACTATTGGCAAC-
GAGCGGTT
39 and
59TGTCAGCAATGCCTGGGTACAT
39.
Results
Inhibition of translation elongation can alter
chemosensitivity
A large number of translation elongation inhibitors have been
tested in NIH’s Developmental Therapeutics Program to assess
the chemotherapeutic potential of small molecules in various
mouse cancer models as single agents (Fig. S1). A significant
fraction of these show activity, although in many cases, these
results are restricted to a single dose, delivery route, or cancer
model. In addition, a shortcoming of these assays is that they do
not assess for a compounds’ ability to modulate chemosensitivity.
We therefore chose to use the Em-Myc lymphoma model to assess
the anti-cancer and chemosensitization activity of translation
elongation inhibitors. In this study, we used four structurally
different elongation inhibitors: HHT, CHX, Bru, and Did B
(Fig. 1A). HHT and Bru inhibit the first steps of elongation
whereas Did B and CHX block translocation by interfering with
elongation factor and E site function, respectively ([25], and this
report).
Compounds were tested in combination with Dxr, using a
delivery regiment consisting of 5 daily injections of compound,
with delivery of one bolus of Dxr on the second day of treatment
[16]. For these studies, we used mice bearing Pten
+/2Em-Myc
lymphomas since mTOR is activated in these tumors and they
respond to the combination of Dxr and Rap treatment [16], as
well as to combinations of Dxr and the translation initiation
inhibitor, silvestrol [17]. As single agents, none of the elongation
inhibitors tested induced remissions (Fig. 1B). Dxr and Rap as
single agents induced a slight remission that lasted on average 5
days, as previously reported [17]. In contrast, all four elongation
inhibitors and Rap synergized with Dxr to extend the tumor-free
period and overall survival 2–3 fold (Figs 1B and S2). Enhanced
drug sensitivity was associated with increased apoptosis for all drug
treatment combinations, compared to single agent treatments
(Fig. 1C). Consistent with this interpretation, the observed
enhanced sensitivity to Dxr/elongation inhibitor combination
was also associated with elevated PARP cleavage (Fig. 1D). As
single agents, none of the inhibitors significantly induced PARP
cleavage (Fig. 1D).
To assess the efficacy of translation elongation inhibitors on
Rap-resistant lymphomas, we examined the activity of these
compounds on Em-Myc/eIF4E lymphomas. These lymphomas
over-express eIF4E and are resistant to Dxr+Rap combination
treatment [6,16] (Fig. 2A), but sensitive to the combination of Dxr
and silvestrol, an eIF4A activity modulator [17]. As observed with
Pten
+/2Em-Myc lymphomas, treatment of mice bearing Em-Myc/
eIF4E lymphomas with any of the elongation inhibitors alone was
not effective in inducing remissions (Fig. 2A). Treatment with Dxr,
Rap, or Rap+Dxr caused a short-lived remission (,5 days) in
,50% of the mice (Fig. 2A). However, combination therapy with
any one of the four translation inhibitors and Dxr produced
tumor-free remissions that lasted up to 25 days (Fig. 2A) and also
extended the survival of the mice (Fig. S3A). We do not believe
that an inherent feature of Em-Myc lymphomas make them
particularly sensitive to the effects of elongation inhibitor/Dxr
combination since Em-Myc/Bcl-2 lymphomas showed significant
resistance to these drug combinations (Fig. 2B). Bcl-2 was able to
protect against PARP cleavage by these treatments (Fig. 2C). All
treatments that extend the tumor-free period in mice bearing Em-
Myc/eIF-4E lymphomas had no effect on overall survival in mice
bearing Em-Myc/Bcl-2 tumors (Fig. S3B).
Degradation of short-lived proteins following exposure
to translation elongation inhibitors
Several of the proteins that play important regulatory roles in
cancer progression and apoptosis have short half-lives (e.g. cyclin
D1 (,25 min) [26]; c-Myc (,25 min) [27]; myeloid cell leukemia-
1 (Mcl-1) (,40 min) [28]. The level of these proteins is particularly
sensitive to ongoing protein synthesis rates and can be affected by
cellular stresses or treatment with translation inhibitors in cell
culture. For example, the anti-apoptotic factor Mcl-1, a short-lived
Bcl-2 family member essential for normal haematopoiesis and
constitutively targeted to the proteasome by the E3 Ligase MULE
[29], is rapidly degraded upon UV-irradiation [30] or HHT
treatment [31]. c-Myc protein levels have been shown to rapidly
decline upon CHX treatment [32]. Since the inhibitors we were
using are predicted to affect global translation, we rationalized that
one mechanism by which they could be affecting survival is
through allowing the rapid loss of short-lived pro-survival factors
from cells treated with translation inhibitors to facilitate pro-
apoptotic triggering.
We then sought to verify the levels of three short-lived proteins
in vivo in Pten
+/2Em-Myc lymphomas treated in tumor-bearing mice
(Fig. 3). Following delivery of 2 doses of compound over a 24-hr
period, tumors were isolated 4 hrs after the 2
nd injection. By
28 hrs post-drug delivery, there was a reduction in the amount of
Mcl-1, Cyclin D1, and c-Myc protein levels in Pten
+/2Em-Myc
lymphomas relative to vehicle-treated controls (Fig. 3A, compare
lanes 2–6 to 1) whereas the levels of b-actin or Bcl-2 did not
appreciably change over this time period. Using the same
treatment schedule, no significant change in Mcl-1, cyclin D1,
and c-Myc mRNA level was observed in the tumors with the
elongation inhibitors (Fig 3B).
HHT and Bru block translation in Pten
+/2Em-Myc
lymphomas
To provide direct evidence that the compounds being used
actually are targeting the translation process in tumor cells in vivo;
we analyzed the polyribosome content of Pten
+/2Em-Myc tumors
from mice treated with the elongation inhibitors. We focussed on
HHT and Bru, since the polysomes from CHX or Did B treated
tumors would resemble untreated controls, as both of these
Translation and Chemotherapy
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Although HHT and Bru are regarded as elongation inhibitors,
their mode of action has not been well defined. Both compounds
inhibit the peptidyl transferase reaction [33,34,35,36] and are
thought to bind tighter to free ribosomes than translating
ribosomes [33,34]. When added to actively translating reactions,
there is a 2–4 minute lag before onset of inhibition is observed
[33,37], suggesting that the compounds allow ribosome run-off.
To obtain more direct evidence that both these compounds block
elongation and do not affect ribosome loading, we tested their
ability to counter the formation of the CHX-induced stable 80S
complexes on mRNA templates in in vitro ribosome binding assays.
Sedimentation velocity centrifugation was used to separate 80S
complexes from unbound radiolabelled mRNA (Fig. S4). HHT
and Bru were thus tested in combination with CHX, to monitor
their effect on ribosome loading. The results indicate that, both
HHT and Bru do not significantly interfere with the trapping of
80S complexes by CHX when compared to the binding obtained
without CHX. Furthermore, when tested as single agents in this
assay, HHT and Bru induce a peak comparable in height to the
one obtained with CHX alone (data not shown). Taken together
with the fact that these compounds allow ribosome run-off, we
conclude that they do not affect ribosome loading but rather block
the first step of elongation. The polyribosomal content of Pten
+/2
Em-Myc tumors that had been treated with vehicle, HHT, or Bru
indicates a drop in the polyribosomal content of the HHT2 and
Bru-treated tumors with a concomitant increase in amount of 80S
ribosomes (Fig. 4). We found that the polysome to monosome ratio
(P/M) in drug-treated tumors decreased ,4–6 fold compared to
vehicle-treated samples (Fig. 4).
Figure 1. Translation elongation inhibitors alter the chemosensitivity of Pten
+/2Em-Myc lymphomas. A. Schematic diagram illustrating
the chemical structure of elongation inhibitors used in this study. B. Kaplan-Meier curves representing the time to relapse following treatment of
mice bearing Pten
+2Em-Myc tumors. Ten animals were treated in each cohort. All mice were treated at the same time and in the same experiment, but
the data is presented as two curves for ease of visualization. P,0.001 for significance among all curves of combination treatments compared to single
agent treatments, as determined by the log rank test. C. Translation elongation inhibitors potentiate the apoptotic program induced by Dxr in
Pten
+/2Em-Myc lymphomas in vivo. Representative micrographs of Pten
+/2Em-Myc lymphomas following treatments (original magnification, 6200).
Mice were first treated with elongation inhibitors or Rap and injected again 24 hrs later with the same compounds with or without combination
treatment with Dxr. Four hours later, tumors were extracted and processed for TUNEL analysis. The percentage of cells that stained positive is
indicated at the top right and represents the average of three different fields where 500 cells were counted per field. This experiment was repeated
three times with similar results. D. Representative Western blot analysis of Pten
+/2Em-Myc lymphomas treated as described in (C). Tumor cells were
extracted, lysed, and the levels of cleaved-PARP (c-PARP) and a-tubulin determined by Western blotting. This experiment was performed on three
independent tumor samples with similar results.
doi:10.1371/journal.pone.0005428.g001
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+/2
Em-Myc tumors treated with translation elongation
inhibitors
We next addressed whether the decrease in Mcl-1, Cyclin D1,
and c-Myc observed upon treatment of Pten
+/2Em-Myc tumors
with elongation inhibitor was due to a reduction in their
translation. To this end, we isolated RNA from fractions that
spanned the polyribosomes of Pten
+/2Em-Myc tumors taken 2 hr
after treatment with HHT2, Bru- or vehicle (Fig. 4). The relative
amount of mRNA in every second fraction was determined by
qRT-PCR and plotted as a percentage of total mRNA (Fig. 5).
Treatment of mice bearing Pten
+/2Em-Myc tumors with either
HHT or Bru led to a shift in Mcl-1, cyclin D1, c-Myc, and b-actin
mRNAs from heavy polysomes (fractions 20–24) into lighter
polysomes (fractions 6–12), consistent with these compounds
partially inhibiting global protein synthesis in vivo. The reasons
for the partial inhibition of protein synthesis will be addressed in
the Discussion.
Figure 2. Translation elongation inhibitors alter the chemosensitivity of Em-Myc/eIF4E lymphomas. A. Kaplan-Meier curves representing
the time to relapse following treatment of mice bearing Em-Myc/eIF4E tumors. Ten animals were treated in each cohort. All mice were treated at the
same time and in the same experiment, but the data is presented as two curves for ease of visualization. P,0.001 for significance among all curves of
combination treatments involving Bru+Dxr, HHT+Dxr, Did+Dxr, and CHX+Dxr compared to single agent treatments, as determined by the log rank
test. B. Em-Myc/Bcl-2 tumors are highly resistant to the combination of translation elongation inhibition and Dxr in vivo. Kaplan-Meier plot showing
tumor-free survival of mice (n=10 for each cohort) bearing Em-Myc/Bcl-2 tumors following treatment. Log rank analysis of the curves of combination
relative to single agent treatments shows a significant difference between Dxr and Rap+Dxr, HHT+Dxr, Did+Dxr and Bru+Dxr, but not CHX+Dxr with
P-values of 0.003, 0.002, 0.004, 0.003 and 0.120, respectively. C. Western blot analysis of Em-Myc/Bcl-2 lymphomas treated as indicated above the
panel. Tumor cells were extracted, lysed, and the levels of cleaved-PARP (c-PARP) and a-tubulin determined by Western blotting. The Western blots
were performed on two independent tumor samples with similar results.
doi:10.1371/journal.pone.0005428.g002
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associated with the synergistic effects observed between inhibitors
of elongation and Dxr, then one might expect that the presence of
a proteasome inhibitor in this system might antagonize the effects
of protein synthesis blockade. For this purpose, we used Tsc2
+/2
Em-Myc lymphomas cultured ex vivo [20]. As documented for
Pten
+/2Em-Myc lymphomas, inhibiting translation elongation in
Tsc2
+/2Em-Myc lymphomas also synergizes with Dxr to induce
remissions in mice that lasted for up to 28 days (Fig. S5A). Rap
also synergized with Dxr in this setting as previously established
[4] and was able to inhibit mTOR activity as determined by p-S6
blotting (Fig. S5B). As well, HHT is able to block translation in
mice bearing Tsc2
+/2Em-Myc lymphomas as revealed by polysome
analysis of tumors two hours following compound administration
(Fig. S5C). Tsc2
+/2Em-Myc lymphomas were cultured ex vivo and
exposed for various times to a concentration of compound
sufficient to completely block global protein synthesis (Fig. S6).
Treatments also included a 30-min pre-exposure to the protea-
Figure 3. Inhibition of translation elongation in mice bearing Pten
+/2Em-Myc lymphomas leads to reduced amounts of Mcl-1, Cyclin
D1, and c-Myc. Mice bearing Pten
+/2Em-Myc tumors were treated for 28 hrs (two injections; 24 hrs apart) with either Rap (4 mg/kg), HHT (0.25 mg/
kg), Bru (0.5 mg/kg), Did B (0.05 mg/kg) or CHX (12.5 mg/kg). A. At 28 hrs (lanes 2–6) tumor cells were extracted, lysed, and proteins fractionated by
SDS-PAGE followed by Western blot analysis. The vehicle control mice were treated like the 28 hrs compound treatments except that compounds
were omitted. B. Assessment of mRNA levels in Pten
+/2Em-Myc tumors by qRT-PCR. The change in mRNA amounts relative to vehicle-treated controls
(V) from three independent experiments is shown as a bar graph with standard deviation. Quantitation of the data from three independent
experiments performed as in A is also superimposed on these graphs.
doi:10.1371/journal.pone.0005428.g003
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Mcl-1, c-Myc, Cyclin D1 and b-actin were determined by Western
blotting (Fig. 6A–D). As predicted, exposure of cells to HHT, Did
B, Bru or CHX lead to a drastic reduction in Mcl-1, cyclin D1,
and c-Myc protein levels (compare lanes 2–4 to lane 1). Consistent
with this being a selective loss of proteins, b-actin levels did not
significantly change (Fig. 6A–D, compare lanes 2–4) nor was the
Coomassie-visible protein profile altered (data not shown) when
comparing pre- and post-drug exposure. Pre-exposure of cells to
MG132 followed by addition of elongation inhibitors strongly
blocked the reduction in Mcl-1, Cyclin D1, and c-Myc protein
levels (Fig. 6A–D, compare lanes 6–8 to 2–4). Given this result, we
sought to determine what effect MG132 would have on HHT2 or
Rap-induced cell death in Tsc2
+/2Em-Myc lymphomas. Tumor
cells were exposed to HHT or Rap in the presence or absence of a
fixed concentration of MG132 (10 mM) and cell viability
determined (Fig 7A). The results indicate that inhibition of the
proteasome antagonizes the toxicity of HHT and Rap on these
cells with at least 2–3 fold more cells surviving at the highest dose
of translation inhibition tested. These results are in agreement with
previous work that showed that MG132 can protect against CHX-
induced apoptosis in U397 cells [39]. To assess if MG132 would
also antagonize the synergy we observed between elongation
inhibitors and Dxr, we exposed Tsc2
+/2Em-myc lymphomas to
HHT or Rap with Dxr. Median effect analysis indicated a
combination index (CI) below 1 for Dxr+HHT and Rap+Dxr
indicative of synergy [40] (Fig 7B). The presence of MG132
antagonized both Dxr+HHT and Dxr+Rap combinations, with
CI values extending above 1 (Fig 7B). The ability of the
proteasome inhibitor MG132 to curtail the synergy between
HHT and Dxr is consistent with HHT modulating drug sensitivity
by causing loss of short-lived pro-survival factors.
Discussion
Inhibitors of elongation have been previously tested in murine
cancer models for their anti-cancer properties as single agents (Fig.
S1), as well as identified as genotype-selective antitumor agents in
synthetic lethal screens [41]. The potential synergy between
translation elongation inhibitors and DNA damaging agents has
only been tested in cell culture. CHX has been reported to
enhance the cytotoxicity of the anthracycline, epirubicin, against
P388 murine leukemic cells [42] and to potentiate Dxr toxicity in
RKO-E6 cells [43]. Sparsomycin, pretazettine, and HHT also
show synergy with antitumor agents against tumor cells ex vivo
[44,45,46,47]. Finally, translation elongation inhibitors have been
shown to sensitize PC3 cells to TRAIL-induced apoptosis [48] and
A549 lung cancer or K562 leukemia cells to cisplatin [49]. In other
settings however, CHX and anguidine have protected cells against
the cytotoxic effects of antitumor drugs [50,51,52]. Differences in
underlying genetic lesions among tumors could be responsible for
these different responses [53]. Despite the large amount of studies
documenting the behaviour of translation elongation inhibitors in
cell lines, testing the potential of elongation inhibitors to synergize
with standard-of-care agents in animal models has not been
systematically approached.
We demonstrate here that the elongation inhibitors HHT, Bru,
Did B and CHX modulate the chemosensitivity of Pten
+/2Em-Myc,
Tsc2
+/2Em-Myc and Em-Myc/eIF4E tumors to the effects of Dxr
whereas Em-Myc/Bcl2 tumors were largely refractory to combina-
tion therapy. These treatments in the Pten
+/2Em-Myc induce an
apoptotic response in these chemoresistant tumors as determined
by TUNEL analysis and PARP cleavage (Fig. 1). The mechanism
by which inhibitors modulate chemoresponsiveness remains to be
clearly established, but at the doses tested we observed a
correlation between tumor disappearance and inhibition of
translation in the tumors (Fig 4A). However, we note that only
partial inhibition of protein synthesis was observed in vivo with
these compounds (Figs. 4A and 5). Pharmacological properties of
some of these compounds (serum binding, serum half-life,
clearance, or cell permeability) may be the underlying reason
why some inhibitors function better than others. The terminal
half-life of HHT has been determined to be 14.4 hrs in human
Figure 4. A. HHT and Bru inhibit polysome formation in Pten
+/2Em-Myc tumors. Mice bearing well-palpable Pten
+/2Em-Myc tumors were treated with
either vehicle (DMSO), HHT (0.25 mg/kg), or Bru (0.5 mg/kg). Two hours later, tumors were harvested and cell extracts prepared and fractionated
through 10%–50% sucrose gradients. Polyribosomes were monitored by measuring the OD260 using an ISCO UA-6 UV detector. The experiment was
repeated two more times with similar results.
doi:10.1371/journal.pone.0005428.g004
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blood of human patients is biphasic with apparent half-lives of 0.12
and 4.8 hrs [56] and its observed terminal half-life in mice is
16.2 hrs [57]. The elimination half-life of Bru in mice has been
estimated to be greater than 12 hrs and in human serum it is
biphasic and progresses through an initial fast half-life of 15 min
followed by a second half-life of 0.7–13.8 hrs depending on the
patients [58]. Clearly, these compounds display a wide range of
pharmacokinetic and pharmacodynamic behaviour.
Our results suggest that a decrease in the levels of factors, like
Mcl-1, cyclin D1, and c-Myc might reorganize the onco-proteome
allowing transformed cells to become sensitive to Dxr through
mechanisms that include re-establishment of the apoptotic
program (Fig. 1C). The role of Mcl-1 in enhancing cell survival
by blocking activation of the pro-apoptotic factors Bak and Bax
has been well-established in culture [39,59,60] and c-Myc controls
the expression of genes involved in many aspects of cell growth
including cell cycle progression and survival [61]. Cyclin D1 has
been shown to bind to CDK4 and CDK6 leading to inactivation
of Rb1, thus facilitating the transition from G1 to S phase and
overcoming the transition inhibition by cyclin dependent kinase
inhibitors [62,63]. It is noteworthy that as single agents, none of
these compounds showed activity in the Em-myc model, compared
to other mouse models where activity was sometimes detected (Fig.
S1). Similar results have been documented for the mTOR
inhibitor, rapamycin [5,6], and the eIF4A modulator, silvestrol
[17], and suggests that the tumors derived from the Em-Myc model
require a DNA damage trigger to undergo apoptosis when
translation is inhibited.
Many possiblities could explain the resistance of the Em-Myc/
Bcl-2 tumors to Dxr/elongation inhibitor combination (Fig. 2B).
This could be due to the longer half-life of this anti-apoptotic
factor (,10 hrs) [64] combined to the only partial inhibition of
protein synthesis achieved in vivo by these compounds (Fig. 5).
Alternatively, reduced levels of short-lived proteins (e.g. Mcl-1,
cyclin D1, or c-Myc) could be better tolerated in the Em-Myc/Bcl-2
tumors than in the other models. Further work would be required
to formally demonstrate the mechanism of resistance by Bcl-2
overexpression in this mouse model. We cannot exclude the
possibility that the compounds tested herein modulate the
cytotoxicity of Dxr through other mechanisms, such as affecting
serum half-life of Dxr, increasing intracellular drug levels by
altering the expression of polypeptide(s) involved in transport, or
by affecting detoxification [49].
Why would inhibiting translation elongation achieve a thera-
peutic index, since it is expected that translation of all mRNAs
would be inhibited to the same extent by such inhibitors? It is
possible that, by having higher translation rates [4,65] transformed
cells are more sensitive to these compounds even when they exert
partial inhibitory activity. Alternatively, as the cells transform into
cancer cells, they are thought to select for higher oncogene activity
or expression and become ‘‘addicted’’ to these oncogenes [66].
Some of these oncogenic proteins possess short half-lives and are
likely to be selectively depleted by elongation inhibitors driving the
transformed cells towards apoptosis. Our work provides a rationale
for using elongation inhibitors to modulate chemosensitivity in
tumors.
Supporting Information
Figure S1 Results summarizing in vivo screening data from the
NIH Developmental Therapeutics Program for translation
inhibitors in various mouse cancer models. The data for each
compound was obtained from http://dtp.nci.nih.gov/dtpstandard/
dwindex/index.jsp and manually inspected. A positive response
in a given model was noted if the Treated/Control cohorts
showed a value greater than 125% for any of the given doses,
administration routes, or delivery vehicles. The height of the bar
graph denotes the total number of different cancer models
reported and the open portion of the bar denotes the number of
models in which the indicated compound showed activity at
least once.
Found at: doi:10.1371/journal.pone.0005428.s001 (2.07 MB TIF)
Figure S2 Translation elongation inhibitors potentiate the
activity of Dxr to extend overall survival of mice bearing Pten+/
Figure 5. Treatment of mice with HHT and Bru inhibits general
protein synthesis in vivo. Pten
+/2Em-Myc tumors were isolated from
HHT2 or Bru- treated animals and their polyribosomes fractionated on
10–50% sucrose gradients. RNA was purified from the indicated
fractions and quantified using qRT-PCR for Mcl-1, cyclin D1, c-Myc
and b-actin levels. The amount of mRNA in each fraction was
determined relative to vehicle-treated mice. The values are averaged
from three independent experiments and the error bars denote the
error of mean (n=3).
doi:10.1371/journal.pone.0005428.g005
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overall survival of mice bearing Pten+/2Em-Myc tumors following
treatment. Ten animals were treated in each cohort. All mice were
treated at the same time and in the same experiment, but the data
is presented as two curves for ease of visualization. P,0.001 for
significance among all curves of combination relative to single
agent treatments, as determined by the log rank test.
Found at: doi:10.1371/journal.pone.0005428.s002 (1.20 MB TIF)
Figure S3 Overall survival in mice bearing Em-Myc/eIF4E or
Em-Myc/BCL2 lymphomas treated with translation elongation
inhibitors. A. Kaplan-Meier curves representing the overall
survival of mice bearing Em-Myc/eIF4E tumors following treat-
ment. Ten animals were treated in each cohort. All mice were
treated at the same time and in the same experiment, but the data
Figure 6. MG132 antagonizes the effects of elongation inhibitors on the levels of Mcl-1, Cyclin D1, and c-Myc. Tsc2
+/2Em-Myc
lymphomas were pre-treated with MG132 (lanes 5–8) or vehicle (lanes 1–4) for 30 min and exposed to HHT (100 nM) (A), Did B (100 nM) (B), Bru
(100 nM) (C) or CHX (1 mM) (D) for the indicated periods of time (lanes 1–8). At the end of each incubation, the cells were harvested, lysed and the
levels of Mcl-1, cyclin D1, c-Myc and b-actin determined by Western blotting. The right panel of each gel shows the intensities of each band relative to
the 0 hr control with standard deviation from three independent experiments.
doi:10.1371/journal.pone.0005428.g006
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significance among all curves of combination relative to single
agent treatments, as determined by the log rank test. B. Kaplan-
Meier curves representing the overall survival of mice bearing
Em-Myc/BCL2 tumors following treatment. Ten animals were
treated in each cohort. All mice were treated at the same time
and in the same experiment, but the data is presented as two
curves for ease of visualization. Log rank analysis of the
treatment responses indicates a significant difference between
Dxr and Rap+Dxr having a P-value,0.001. The analysis also
indicates that the curve obtained with Dxr alone is not
significantly different than the ones obtained with HHT+Dxr,
Did+Dxr, Bru+D x ro rC H X +Dxr with respective P-values of
0.0149, 0.0241, 0.245 and 0.101.
Found at: doi:10.1371/journal.pone.0005428.s003 (1.83 MB TIF)
Figure S4 HHT and Bru trap 80S complexes on mRNA
templates. Rabbit reticulocyte lysates were preincubated without
compound, with 0.6 mM CHX, 10 mM HHT+0.6 mM CHX or
10 mM Bru+0.6 mM CHX at 30uC for 5 min. The reactions were
then supplemented with [
32P]-radiolabeled CAT mRNA and
incubated for an additional 10 min at 30uC. 80S complexes were
resolved by centrifugation through 10–30% glycerol gradients.
The direction of the arrow indicates the orientation of the
gradient, from top to bottom. The total counts recovered from
each gradient and the percent mRNA bound in 80S complexes
were: CHX (left panel) [26,960 cpm, 20.0% binding],
HHT+CHX [28,383 cpm, 16.8% binding], no compound
[5744 cpm, 3.4% binding], CHX (right panel) [71,727 cpm,
17.4% binding], and Bru+CHX [50,392 cpm, 12.2% binding]
and no compound [11,542 cpm, 2.8% binding].
Figure 7. MG132 antagonizes the toxicity of HHT and Rap on Tsc2
+/2Em-Myc lymphomas and interferes with their Dxr-associated
synergism. A. Cells were exposed to the indicated concentrations of HHT or Rap in the presence or absence of 10 mM MG132. Cell viability was
determined 16 hrs later. The results are presented as the fraction of viable cells relative to vehicle (0.02% DMSO) treated samples with the standard
deviation presented (n=3). B. Lymphomas cells were treated with increasing concentrations and HHT and Dxr or Rap and Dxr at a fixed ratio in
presence or absence of a fixed MG132 concentration (10 mM) for 16 hrs and the cell viability was determined. A CI value below 1 indicates a
synergistic effect whereas a value above 1 represents antagonism. These experiments were performed three times with similar results.
doi:10.1371/journal.pone.0005428.g007
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Figure S5 Translation elongation inhibitors potentiate the
activity of Dxr to extend overall survival of mice bearing Tsc2+/
2Em-Myc lymphomas. A. Kaplan-Meier curves representing the
tumor-free period in mice bearing Tsc2+/2Em-Myc tumors
following treatment. Ten animals were treated in each cohort.
P,0.001 for significance among all curves of combination relative
to single agent treatments, as determined by the log rank test. B.
Western blot analysis of Rap treatments of mice bearing Em-Myc
(lanes 1 to 2), Pten+/2Em-Myc (lanes 3 to 4) or Tsc2+/2Em-Myc
(lanes 5 to 6) tumors. Mice were treated for 4 hours with 4 mg/kg
of Rap, the tumors extracted and cell lysates prepared and
analysed for pan- and p-S6 levels. C. HHT blocks protein
synthesis in Tsc2+/2Em-Myc lymphomas in vivo. Mice bearing
Tsc2+/2Em-Myc lymphomas were treated and polysomes ana-
lyzed as described in the legend to Figure 4. These experiments
were performed for a total of three replicates with similar results.
Found at: doi:10.1371/journal.pone.0005428.s005 (1.64 MB TIF)
Figure S6 Potency of the elongation inhibitors at inhibiting
translation in Tsc2+/2Em-Myc lymphomas. Two hundred and
fifty thousand cells were plated in 24-well plates in BCM in
presence of increasing concentrations of HHT, Bru, Did B or
CHX and incubated for 3 hours followed by a
35S-methionine
labelling performed 20 minutes before the end of the incubation.
The results are expressed as cpm/ug of total protein relative to
DMSO control (n=3).
Found at: doi:10.1371/journal.pone.0005428.s006 (1.55 MB TIF)
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